Animal Models for Parkinson's Disease Research: Trends in the 2000s

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2019 Nov 2

PMID 31671557

Citations 61

Authors

Kyohei Kin

Takao Yasuhara

Masahiro Kameda

Isao Date

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD) is a chronic and progressive movement disorder and the second most common neurodegenerative disease. Although many studies have been conducted, there is an unmet clinical need to develop new treatments because, currently, only symptomatic therapies are available. To achieve this goal, clarification of the pathology is required. Attempts have been made to emulate human PD and various animal models have been developed over the decades. Neurotoxin models have been commonly used for PD research. Recently, advances in transgenic technology have enabled the development of genetic models that help to identify new approaches in PD research. However, PD animal model trends have not been investigated. Revealing the trends for PD research will be valuable for increasing our understanding of the positive and negative aspects of each model. In this article, we clarified the trends for animal models that were used to research PD in the 2000s, and we discussed each model based on these trends.

Citing Articles

A methodological scoping review on EMG processing and synergy-based results in muscle synergy studies in Parkinson's disease.

Lanzani V, Brambilla C, Scano A Front Bioeng Biotechnol. 2025; 12():1445447.

PMID: 39834639 PMC: 11743385. DOI: 10.3389/fbioe.2024.1445447.

Prolonged intermittent theta burst stimulation restores the balance between A2AR- and A1R-mediated adenosine signaling in the 6-hydroxidopamine model of Parkinson's disease.

Jovanovic M, Stanojevic J, Stevanovic I, Ninkovic M, Ilic T, Nedeljkovic N Neural Regen Res. 2024; 20(7):2053-2067.

PMID: 39254566 PMC: 11691459. DOI: 10.4103/NRR.NRR-D-23-01542.

Construct, Face, and Predictive Validity of Parkinson's Disease Rodent Models.

Guimaraes R, Resende M, Tavares M, Belardinelli de Azevedo C, Ruiz M, Mortari M Int J Mol Sci. 2024; 25(16).

PMID: 39201659 PMC: 11354451. DOI: 10.3390/ijms25168971.

Unraveling the AKT/ERK cascade and its role in Parkinson disease.

Keshri P, Singh S Arch Toxicol. 2024; 98(10):3169-3190.

PMID: 39136731 DOI: 10.1007/s00204-024-03829-9.

Benfotiamine protects MPTP-induced Parkinson's disease mouse model via activating Nrf2 signaling pathway.

Wang K, Han C, Yang J, Xu W, Wang L, Li H PLoS One. 2024; 19(7):e0307012.

PMID: 39042624 PMC: 11265681. DOI: 10.1371/journal.pone.0307012.

References

Billings J, Hare D, Nurjono M, Volitakis I, Cherny R, Bush A . Effects of Neonatal Iron Feeding and Chronic Clioquinol Administration on the Parkinsonian Human A53T Transgenic Mouse. ACS Chem Neurosci. 2015; 7(3):360-6. DOI: 10.1021/acschemneuro.5b00305. View

Kuruvilla K, Nandhu M, Paul J, Paulose C . Oxidative stress mediated neuronal damage in the corpus striatum of 6-hydroxydopamine lesioned Parkinson's rats: neuroprotection by serotonin, GABA and bone marrow cells supplementation. J Neurol Sci. 2013; 331(1-2):31-7. DOI: 10.1016/j.jns.2013.04.020. View

Dawson T, Dawson V . The role of parkin in familial and sporadic Parkinson's disease. Mov Disord. 2010; 25 Suppl 1:S32-9. PMC: 4115293. DOI: 10.1002/mds.22798. View

Bonifati V, Rizzu P, van Baren M, Schaap O, Breedveld G, Krieger E . Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2002; 299(5604):256-9. DOI: 10.1126/science.1077209. View

Schulte C, Gasser T . Genetic basis of Parkinson's disease: inheritance, penetrance, and expression. Appl Clin Genet. 2013; 4:67-80. PMC: 3681179. DOI: 10.2147/TACG.S11639. View

Cui M, Aras R, Christian W, Rappold P, Hatwar M, Panza J . The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc Natl Acad Sci U S A. 2009; 106(19):8043-8. PMC: 2683105. DOI: 10.1073/pnas.0900358106. View

Gash D, Rutland K, Hudson N, Sullivan P, Bing G, Cass W . Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity. Ann Neurol. 2007; 63(2):184-92. DOI: 10.1002/ana.21288. View

Matsuda N, Sato S, Shiba K, Okatsu K, Saisho K, Gautier C . PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol. 2010; 189(2):211-21. PMC: 2856912. DOI: 10.1083/jcb.200910140. View

Singleton A, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J . alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003; 302(5646):841. DOI: 10.1126/science.1090278. View

10.

Kim R, Smith P, Aleyasin H, Hayley S, Mount M, Pownall S . Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci U S A. 2005; 102(14):5215-20. PMC: 555037. DOI: 10.1073/pnas.0501282102. View

11.

Kim A, Nigmatullina R, Zalyalova Z, Soshnikova N, Krasnov A, Vorobyeva N . Upgraded Methodology for the Development of Early Diagnosis of Parkinson's Disease Based on Searching Blood Markers in Patients and Experimental Models. Mol Neurobiol. 2018; 56(5):3437-3450. DOI: 10.1007/s12035-018-1315-2. View

12.

Lim K, Ng C . Genetic models of Parkinson disease. Biochim Biophys Acta. 2008; 1792(7):604-15. DOI: 10.1016/j.bbadis.2008.10.005. View

13.

Kaur D, Peng J, Chinta S, Rajagopalan S, Di Monte D, Cherny R . Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiol Aging. 2006; 28(6):907-13. DOI: 10.1016/j.neurobiolaging.2006.04.003. View

14.

Moore D, Dawson T . Value of genetic models in understanding the cause and mechanisms of Parkinson's disease. Curr Neurol Neurosci Rep. 2008; 8(4):288-96. PMC: 4431569. DOI: 10.1007/s11910-008-0045-7. View

15.

Creed R, Goldberg M . New Developments in Genetic rat models of Parkinson's Disease. Mov Disord. 2018; 33(5):717-729. PMC: 5992003. DOI: 10.1002/mds.27296. View

16.

Luk K, Kehm V, Carroll J, Zhang B, OBrien P, Trojanowski J . Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012; 338(6109):949-53. PMC: 3552321. DOI: 10.1126/science.1227157. View

17.

Manning-Bog A, McCormack A, Li J, Uversky V, Fink A, Di Monte D . The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem. 2001; 277(3):1641-4. DOI: 10.1074/jbc.C100560200. View

18.

Vercammen L, Van der Perren A, Vaudano E, Gijsbers R, Debyser Z, Van den Haute C . Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease. Mol Ther. 2006; 14(5):716-23. DOI: 10.1016/j.ymthe.2006.06.009. View

19.

Kara E, Kiely A, Proukakis C, Giffin N, Love S, Hehir J . A 6.4 Mb duplication of the α-synuclein locus causing frontotemporal dementia and Parkinsonism: phenotype-genotype correlations. JAMA Neurol. 2014; 71(9):1162-71. PMC: 4362700. DOI: 10.1001/jamaneurol.2014.994. View

20.

Yeo G, Van Nostrand E, Holste D, Poggio T, Burge C . Identification and analysis of alternative splicing events conserved in human and mouse. Proc Natl Acad Sci U S A. 2005; 102(8):2850-5. PMC: 548664. DOI: 10.1073/pnas.0409742102. View